Development of malaria transmission-blocking vaccines: from concept to product
- PMID: 26003037
- DOI: 10.1016/bs.apar.2015.04.001
Development of malaria transmission-blocking vaccines: from concept to product
Abstract
Despite decades of effort battling against malaria, the disease is still a major cause of morbidity and mortality. Transmission-blocking vaccines (TBVs) that target sexual stage parasite development could be an integral part of measures for malaria elimination. In the 1950s, Huff et al. first demonstrated the induction of transmission-blocking immunity in chickens by repeated immunizations with Plasmodium gallinaceum-infected red blood cells. Since then, significant progress has been made in identification of parasite antigens responsible for transmission-blocking activity. Recombinant technologies accelerated evaluation of these antigens as vaccine candidates, and it is possible to induce effective transmission-blocking immunity in humans both by natural infection and now by immunization with recombinant vaccines. This chapter reviews the efforts to produce TBVs, summarizes the current status and advances and discusses the remaining challenges and approaches.
Keywords: Malaria; Transmission-blocking; Vaccine.
Copyright © 2015 Elsevier Ltd. All rights reserved.
Similar articles
-
Transmission-blocking vaccines: uses and current status of development.Int J Parasitol. 1997 Feb;27(2):183-9. doi: 10.1016/s0020-7519(96)00148-8. Int J Parasitol. 1997. PMID: 9088989 Review.
-
Development of malaria vaccines that block transmission of parasites by mosquito vectors.J Med Invest. 2002 Aug;49(3-4):118-23. J Med Invest. 2002. PMID: 12323000 Review.
-
Evaluation of two sexual-stage antigens as bivalent transmission-blocking vaccines in rodent malaria.Parasit Vectors. 2021 May 7;14(1):241. doi: 10.1186/s13071-021-04743-0. Parasit Vectors. 2021. PMID: 33962671 Free PMC article.
-
Towards clinical development of a Pfs48/45-based transmission blocking malaria vaccine.Expert Rev Vaccines. 2017 Apr;16(4):329-336. doi: 10.1080/14760584.2017.1276833. Epub 2017 Jan 9. Expert Rev Vaccines. 2017. PMID: 28043178 Review.
-
Effects of transmission-blocking vaccines simultaneously targeting pre- and post-fertilization antigens in the rodent malaria parasite Plasmodium yoelii.Parasit Vectors. 2016 Aug 8;9(1):433. doi: 10.1186/s13071-016-1711-2. Parasit Vectors. 2016. PMID: 27502144 Free PMC article.
Cited by
-
Safety and Immunogenicity of Pfs25-EPA/Alhydrogel®, a Transmission Blocking Vaccine against Plasmodium falciparum: An Open Label Study in Malaria Naïve Adults.PLoS One. 2016 Oct 17;11(10):e0163144. doi: 10.1371/journal.pone.0163144. eCollection 2016. PLoS One. 2016. PMID: 27749907 Free PMC article. Clinical Trial.
-
Melittin as a promising anti-protozoan peptide: current knowledge and future prospects.AMB Express. 2021 May 13;11(1):69. doi: 10.1186/s13568-021-01229-1. AMB Express. 2021. PMID: 33983454 Free PMC article. Review.
-
Identification of three ookinete-specific genes and evaluation of their transmission-blocking potentials in Plasmodium berghei.Vaccine. 2016 May 17;34(23):2570-8. doi: 10.1016/j.vaccine.2016.04.011. Epub 2016 Apr 12. Vaccine. 2016. PMID: 27083421 Free PMC article.
-
Plant-Mediated Effects on Mosquito Capacity to Transmit Human Malaria.PLoS Pathog. 2016 Aug 4;12(8):e1005773. doi: 10.1371/journal.ppat.1005773. eCollection 2016 Aug. PLoS Pathog. 2016. PMID: 27490374 Free PMC article.
-
Assessment of Pfs25 expressed from multiple soluble expression platforms for use as transmission-blocking vaccine candidates.Malar J. 2016 Aug 11;15(1):405. doi: 10.1186/s12936-016-1464-6. Malar J. 2016. PMID: 27515826 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical